Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2020) 70 AEP466 | DOI: 10.1530/endoabs.70.AEP466

1Hospital Vital Álvarez-Buylla, Endocrinology, Santullano, Spain; 2Central University Hospital of Asturias, Endocrinology, Oviedo, Spain; 3Hospital Vital Álvarez-Buylla, Cardiology, Santullano, Spain; 4Hospital Vital Álvarez-Buylla, Hospital Pharmacy, Santullano, Spain


Introduction: Familial hypercholesterolemia (FH) is a genetic disorder characterized by high levels of LDL cholesterol (LDL-C) from birth. Treatment with statins and ezetimibe achieves in most cases large reductions in LDL-C. In those patients in whom the reduction in LDL-C is insufficient or who have intolerance to such treatments, the appearance of PCSK9 inhibitors has been an effective and safe alternative to achieve the LDL-C objectives.

Materials and methods: The results of the lipid profile of patients with FH treated with PCSK9 inhibitors in healthcare areas IV and VII of Asturias (Spain) were retrospectively analyzed. The indications for its use are those included in the consensus document of the Spanish Society of Atherosclerosis (2016).

Results: Data were obtained from 46 patients with FH treated with PCSK9 inhibitors, with a mean follow-up of 20.6 months. The average age was 59.13 years, with a similar distribution by sex (52.2% male).

Table 1 Evolution of medians of total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C) and triglycerides (TG) at the beginning of treatment, 2, 6, 12 and 24 months.
TC (mg/dl)LDL-C (mg/dl)HDL-C (mg/dl)TG (mg/dl)
Initial264,518945124
2 months1396747115
6 months1607546111
12 months1597550102,5
24 months1658051103

 

Table 2 Evolution of TC, LDL-C, HDL-C and TG at the beginning of treatment, 2, 6, 12 and 24 months expressed as a percentage.
TCLDL-CHDL-CTG
2 months– 47,45%– 64,55%+ 4,44%– 7,26%
6 months– 39,5%– 60,32%+ 2,22%– 10,48%
12 months– 39,89%– 60,32%+ 11,11%– 17,34%
24 months– 37,62%– 57,67%+ 13,33%– 16,94%

Conclusions: PCSK9 inhibitors are an effective treatment alternative for patients with FH. Although its maximum effect is achieved 2 months after the start of treatment, its effect is maintained at 2 years, with LDL- C reductions of more than 55%. Likewise, there is a slight increase in HDL-C and a moderate decrease in TG.

Volume 70

22nd European Congress of Endocrinology

Online
05 Sep 2020 - 09 Sep 2020

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

Authors